Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a clinical-stage biotech like Centessa Pharmaceuticals can feel like navigating a maze of scientific jargon and risk factors. Pipeline updates on orexin agonists, the LockBody immuno-oncology platform, and critical cash-runway disclosures are scattered across hundreds of pages. Missing one footnote could mean overlooking a trial halt or royalty obligation.
Stock Titan’s AI decodes every Centessa Pharmaceuticals quarterly earnings report 10-Q filing and annual report 10-K simplified, surfacing what matters—R&D spend by program, milestone payments, and liquidity outlook. Need to see Centessa Pharmaceuticals insider trading Form 4 transactions? You’ll also get Centessa Pharmaceuticals Form 4 insider transactions real-time as they post, while side-by-side comparisons help you understand Centessa Pharmaceuticals SEC filings explained simply. Even sudden announcements, like the 8-K material events explained when SerpinPC was discontinued, land on your dashboard seconds after they hit EDGAR.
Investors use these insights to:
- Monitor Centessa Pharmaceuticals executive stock transactions Form 4 before key data read-outs
- Track progress of ORX750 and LB101 across filings without sifting through appendices
- Compare quarter-over-quarter spending using understanding Centessa Pharmaceuticals SEC documents with AI
- Review the proxy statement executive compensation details in plain English
Whether you’re preparing a valuation model or answering, “How do I read Centessa Pharmaceuticals earnings report filing analysis?”, Stock Titan delivers the context. Real-time updates, AI-powered summaries, and historical documents ensure you never miss a disclosure again.
Centessa Pharmaceuticals plc (CNTA) reporting person Hussain Iqbal J, General Counsel, executed option exercise and a sale on 08/15/2025. The filing shows the reporting person exercised a share option to acquire 6,000 ordinary shares at an exercise price of $5.84 per share and immediately sold 6,000 ordinary shares at $17.23 per share, leaving 105,386 shares owned directly after the transactions. The Form 4 notes 5,500 ordinary shares are held indirectly by the reporting person’s spouse. The reported sale was effected under a Rule 10b5-1 trading plan adopted on September 14, 2024.
Centessa Pharmaceuticals plc (CNTA) filing a Form 144 notifies a proposed sale of 6,000 common shares to be offered through UBS Financial Services on Nasdaq with an aggregate market value of $103,380.00. The filer reports those shares were acquired the same day, 08/15/2025, by exercising stock options and paid in cash.
The filing also discloses prior sales by the same person, Iqbal Hussain: 12,000 shares sold on 06/24/2025 for $168,218.40 and 6,000 shares sold on 07/15/2025 for $89,566.80. The notice affirms no undisclosed material nonpublic information applies to the seller.
Adage Capital Management, together with principals Robert Atchinson and Phillip Gross, reports beneficial ownership of 8,403,000 ordinary shares of Centessa Pharmaceuticals, representing 6.29% of the outstanding class based on 133,618,774 shares. The shares are ordinary shares underlying ADSs traded under ticker CNTA. The filing shows no sole voting or dispositive power — all voting and dispositive rights are reported as shared — and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing control. The statement contains ownership details and reporting person roles but does not disclose any transaction terms or plans.
Centessa Pharmaceuticals plc (CNTA) reported interim results through June 30, 2025 showing continued clinical progress and a material licensing transaction. For the six months ended June 30, 2025 the company recorded a net loss of $76.5 million versus $81.9 million in the prior year period, with research and development expense of $76.2 million driven primarily by the OX2R agonist programs. Centessa recognized a $15.0 million upfront payment from a LockBody license to Genmab and constrained additional milestone consideration pending achievement. As of June 30, 2025 the company held $404.1 million of cash, cash equivalents and investments and expects those resources to fund operations into mid-2027. The balance sheet shows $109.5 million of long-term debt and an accumulated deficit of $1.07 billion. Operational updates include ORX750 in an ongoing Phase 2a study, IND clearance and Phase 1 initiation for ORX142, and the prior-phase discontinuation of SerpinPC with related termination charges largely paid down.
FAQ
What is the current stock price of Centessa Pharmaceuticals Plc (CNTA)?
What is the market cap of Centessa Pharmaceuticals Plc (CNTA)?
